Czechia· CZ-0194634
KADCYLA
A trastuzumab emtansine product containing trastuzumab emtansine, registered in Czechia by Roche Registration GmbH, Grenzach-Wyhlen. The same ATC class is registered in 14 of our 19 countries.
Checked against SÚKL (Czech Republic) on
Informational only — not a medical device.
Where it is registered
Trastuzumab emtansine is registered in 14 of 19 countries.
Countries holding a registration under ATC L01FD03 (trastuzumab emtansine), each read from that country’s own register.
- This record: Czechia, from SÚKL (Czech Republic)
- 9 of them publish a price we can compare per daily dose
Trastuzumab emtansine · ATC L01FD03
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of trastuzumab emtansine costs, country by country.
Normalised to the WHO defined daily dose (12 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Trastuzumab emtansine · price per daily dose (12 mg)
USD · FX 28 Sept 2026
- CH Switzerland$237.25
The record
At a glance
SÚKL (Czech Republic)- Active substance
- TRASTUZUMAB EMTANSINE
- Manufacturer
- Roche Registration GmbH, Grenzach-Wyhlen
- Country
- Czechia (CZ)
- ATC code
- L01FD03
- ATC class
- Trastuzumab emtansine
- Defined daily dose
- 12 mg, P
- Reimbursed
- Not published by this register
- Source register
- SÚKL (Czech Republic)
- Last checked
- September 28, 2026
Packs & prices · 1
1 priced- cz_kod_sukl01946341CZK 73341
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
256 interactions on record for trastuzumab emtansine.
Graded by severity as the source publishes them — 62 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Trastuzumab emtansine · interactions on record
256 records
- 62 severe
- 194 moderate
Most severe, free to view
- DicoumarolB01AA01severe
- WarfarinB01AA03severe
- HeparinB01AB01severe
- DalteparinB01AB04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Trastuzumab emtansine in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandKadcyla2care4 ApS
- SpainKADCYLA 160 MG POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSIONRoche Registration Gmbh
- United KingdomKadcyla 160mg powder for concentrate for solution for infusion vialsOriginalis B.V.
- NorwayKadcylaRoche Registration GmbH
- PolandKadcylaRoche Registration GmbH
- BelgiumKadcyla 160 mgRoche Registration
- SwedenKadcyla 160 mg Pulver till koncentrat till infusionsvätska, lösningRoche Registration GmbH
- IrelandKadcyla 160 mg powder for concentrate for solution for infusionRoche Registration GmbH
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Kadcyla
- Liechtenstein · Kadcyla
- Norway · Kadcyla
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of SÚKL (Czech Republic). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/981f5776-152e-458c-b1fe-65e0f3b4cf85 GET /v1/drugs/981f5776-152e-458c-b1fe-65e0f3b4cf85?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "INF PLV CSL",
"source": "sukl",
"strength": "160MG",
"pack_size": "1",
"substance": "TRASTUZUMAB EMTANSINE",
"cz_kod_sukl": "0194634",
"product_type": "BT",
"substance_codes": "19060",
"registration_state": "R",
"registration_number": "EU/1/13/885/002"
}See everything about trastuzumab emtansine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.